| Stereochemistry | ABSOLUTE |
| Molecular Formula | C30H46O3 |
| Molecular Weight | 454.6844 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 4 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C
InChI
InChIKey=LVLLALCJVJNGQQ-SEODYNFXSA-N
InChI=1S/C30H46O3/c1-6-30(33,7-2)18-9-8-11-21(3)26-15-16-27-23(12-10-17-29(26,27)5)13-14-24-19-25(31)20-28(32)22(24)4/h8-9,11,13-14,18,21,25-28,31-33H,4,6-7,10,12,15-17,19-20H2,1-3,5H3/b11-8+,18-9+,23-13+,24-14-/t21-,25-,26-,27+,28+,29-/m1/s1
| Molecular Formula | C30H46O3 |
| Molecular Weight | 454.6844 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 4 |
| Optical Activity | UNSPECIFIED |
Seocalcitol (EB 1089) is a vitamin D analog, and agonist of the vitamin D receptor. Antineoplastic activity of seocalcitol was tested in clinical trials against hepatocellular carcinoma, pancreatic, breast and colorectal cancer. Due to inconsistent results of clinical trials, development of seocalcitol was discontinued by Leo Pharma.
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
In a phase II clinical study against hepatocellular carcinoma, Seocalcitol was administered orally at starting doses 10 ug/day.
Route of Administration:
Oral
U937 cells were seeded at 1 × 105 cells/ml in culture flasks at 5ml cells/flask. EB 1089 was added in the concentrations 10-9 - 10-12 M; control cultures received the diluent, 2-propanol. After 96 h, proliferation was assessed by counting of cells, and IC50 was calculated from the dose-response curves.
|
|
TARGET -> AGONIST |
|
||
|
|
PARENT -> DERIVATIVE |
|
Showing 1 to 2 of 2 entries
